The Spine Journal
Volume 8, Issue 1 , Pages 8-20, January 2008

A systematic review of low back pain cost of illness studies in the United States and internationally

  • Simon Dagenais, DC, PhD

      Affiliations

    • Division of Orthopaedic Surgery and Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
    • CAM Research Institute, Irvine, CA, USA
    • Corresponding Author InformationCorresponding author. 25 Corona Ave., Rockcliffe, ON, K1M 1K8, Canada. Tel.: (949) 466-8132; fax: (949) 266-8951.
  • ,
  • Jaime Caro, MD

      Affiliations

    • Division of General Internal Medicine and Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine, McGill University, Montreal, QC, Canada
    • Caro Research Institute, Concord, MA, USA
  • ,
  • Scott Haldeman, DC, MD, PhD

      Affiliations

    • Department of Neurology, University of California, Irvine, CA, USA
    • Department of Epidemiology, University of California, Los Angeles, CA, USA
    • Research Division, Southern California University of Health Sciences, Whittier, CA, USA

Received 25 September 2007; accepted 13 October 2007.

Abstract 

Background context

The economic burden of low back pain (LBP) is very large and appears to be growing. It is not possible to impact this burden without understanding the strengths and weaknesses of the research on which these costs are calculated.

Purpose

To conduct a systematic review of LBP cost of illness studies in the United States and internationally.

Study design/setting

Systematic review of the literature.

Methods

Medline was searched to uncover studies about the direct or indirect costs of LBP published in English from 1997 to 2007. Data extracted for each eligible study included study design, population, definition of LBP, methods of estimating costs, year of data, and estimates of direct, indirect, or total costs. Results were synthesized descriptively.

Results

The search yielded 147 studies, of which 21 were deemed relevant; 4 other studies and 2 additional abstracts were found by searching reference lists, bringing the total to 27 relevant studies. The studies reported on data from Australia, Belgium, Japan, Korea, the Netherlands, Sweden, the UK, and the United States. Nine studies estimated direct costs only, nine indirect costs only, and nine both direct and indirect costs, from a societal (n=18) or private insurer (n=9) perspective. Methodology used to derive both direct and indirect cost estimates differed markedly among the studies. Among studies providing a breakdown on direct costs, the largest proportion of direct medical costs for LBP was spent on physical therapy (17%) and inpatient services (17%), followed by pharmacy (13%) and primary care (13%). Among studies providing estimates of total costs, indirect costs resulting from lost work productivity represented a majority of overall costs associated with LBP. Three studies reported that estimates with the friction period approach were 56% lower than with the human capital approach.

Conclusions

Several studies have attempted to estimate the direct, indirect, or total costs associated with LBP in various countries using heterogeneous methodology. Estimates of the economic costs in different countries vary greatly depending on study methodology but by any standards must be considered a substantial burden on society. This review did not identify any studies estimating the total costs of LBP in the United States from a societal perspective. Such studies may be helpful in determining appropriate allocation of health-care resources devoted to this condition.

Keywords: Low back pain, Cost of illness, Economics

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 FDA device/drug status: not applicable.

 Nothing of value received from a commercial entity related to this manuscript.

PII: S1529-9430(07)00898-4

doi:10.1016/j.spinee.2007.10.005

The Spine Journal
Volume 8, Issue 1 , Pages 8-20, January 2008